论文部分内容阅读
联合化疗是小细胞未分化肺癌(SCLC)首选的治疗方法,但最佳的化疗方案的完全反应率也仅30～50%,而局部复发率却高达70～80%,单纯胸部放疗虽可使局部复发率降至30%,但长期生存率也仅只8～12%。为此,以法国Gustave-Roussy研究所为中心的协作组于1980年起应用化疗和放疗交替治疗作为诱导治疗,以后再用化疗维持的方案治疗了63例经病理证实的SCLC,取得了较好的效果。方法:先化疗2个周期(每周期7天,间隔3周),以后与放疗疗程交替进行,化疗与放疗疗程间休息7天(第一疗程放疗前休息10天),第3个放疗疗程后再连给2个周期化疗(2个化疗周期间相隔3
Combination chemotherapy is the preferred treatment for small cell undifferentiated lung cancer (SCLC), but the optimal response rate for chemotherapy is only 30 to 50%, while the local recurrence rate is as high as 70 to 80%. The local recurrence rate dropped to 30%, but the long-term survival rate was only 8 to 12%. To this end, the collaboration group centered on the Gustave-Roussy Institute in France applied chemotherapy and radiotherapy alternate therapy as induction therapy since 1980, and later treated 63 pathologically confirmed SCLCs with chemotherapy-maintained regimens and achieved better results. Effect. Methods: Chemotherapy 2 cycles (7 days per cycle, interval 3 weeks), alternating with radiotherapy after treatment, 7 days of rest between chemotherapy and radiation therapy (10 days before the first course of radiotherapy), after the 3rd radiotherapy 2 consecutive cycles of chemotherapy (2 weeks apart during 2 cycles of chemotherapy)